Myriad Genetics (NASDAQ:MYGN) reported quarterly earnings results on February 23, 2026 that exceeded analyst expectations.
The Healthcare company reported earnings per share of $0.04, beating the consensus estimate of $-0.05 by $0.09 per share. Revenue came in at $209.8M, beating the estimate of $207.6M.
Myriad Genetics's stock moved following the earnings release. The stock currently trades at $5.05 with a market capitalization of $680.9M.